nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—Triamcinolone—psoriasis	0.0974	0.231	CbGbCtD
Lenalidomide—PTGS2—Betamethasone—psoriasis	0.0836	0.198	CbGbCtD
Lenalidomide—TNFSF11—skeletal joint—psoriasis	0.0529	0.377	CbGeAlD
Lenalidomide—PTGS2—Dexamethasone—psoriasis	0.0486	0.115	CbGbCtD
Lenalidomide—TNFSF11—synovial membrane of synovial joint—psoriasis	0.0401	0.286	CbGeAlD
Lenalidomide—ABCB1—Mycophenolate mofetil—psoriasis	0.0321	0.0763	CbGbCtD
Lenalidomide—ABCB1—Betamethasone—psoriasis	0.0276	0.0654	CbGbCtD
Lenalidomide—ABCB1—Prednisolone—psoriasis	0.0272	0.0646	CbGbCtD
Lenalidomide—ABCB1—Hydrocortisone—psoriasis	0.0258	0.0612	CbGbCtD
Lenalidomide—ABCB1—Prednisone—psoriasis	0.0257	0.061	CbGbCtD
Lenalidomide—ABCB1—Cyclosporine—psoriasis	0.0243	0.0578	CbGbCtD
Lenalidomide—ABCB1—Dexamethasone—psoriasis	0.016	0.0381	CbGbCtD
Lenalidomide—CDH5—endothelium—psoriasis	0.0141	0.1	CbGeAlD
Lenalidomide—ABCB1—Methotrexate—psoriasis	0.0129	0.0306	CbGbCtD
Lenalidomide—PTGS2—skeletal joint—psoriasis	0.00688	0.049	CbGeAlD
Lenalidomide—TNFSF11—tendon—psoriasis	0.00607	0.0433	CbGeAlD
Lenalidomide—Thalidomide—NFKB1—psoriasis	0.00586	0.561	CrCbGaD
Lenalidomide—PTGS2—synovial membrane of synovial joint—psoriasis	0.00522	0.0372	CbGeAlD
Lenalidomide—CDH5—tendon—psoriasis	0.00457	0.0326	CbGeAlD
Lenalidomide—PTGS2—skin epidermis—psoriasis	0.00335	0.0239	CbGeAlD
Lenalidomide—CRBN—tendon—psoriasis	0.0029	0.0207	CbGeAlD
Lenalidomide—Pomalidomide—TNF—psoriasis	0.00279	0.267	CrCbGaD
Lenalidomide—PTGS2—endothelium—psoriasis	0.00243	0.0173	CbGeAlD
Lenalidomide—Thalidomide—TNF—psoriasis	0.0018	0.172	CrCbGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—CRP—psoriasis	0.00178	0.0639	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—ICAM1—psoriasis	0.00144	0.0518	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—NFKBIA—psoriasis	0.00143	0.0514	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—TYK2—psoriasis	0.00133	0.0478	CbGpPWpGaD
Lenalidomide—CDH5—S1P2 pathway—JUN—psoriasis	0.00131	0.0471	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.00109	0.157	CbGdCrCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—JUN—psoriasis	0.00108	0.0387	CbGpPWpGaD
Lenalidomide—PTGS2—skin of body—psoriasis	0.00104	0.0074	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—JUN—psoriasis	0.00095	0.0341	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—STAT3—psoriasis	0.000931	0.0334	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—psoriasis	0.000925	0.0332	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—NFKB1—psoriasis	0.000914	0.0328	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000876	0.126	CbGdCrCtD
Lenalidomide—ABCB1—Allograft Rejection—IL22—psoriasis	0.00086	0.0309	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000851	0.122	CbGdCrCtD
Lenalidomide—PTGS2—tendon—psoriasis	0.000791	0.00563	CbGeAlD
Lenalidomide—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.00066	0.0948	CbGdCrCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—psoriasis	0.000651	0.0234	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—psoriasis	0.00064	0.023	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—psoriasis	0.000531	0.019	CbGpPWpGaD
Lenalidomide—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000528	0.076	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000528	0.076	CbGdCrCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—TYK2—psoriasis	0.000522	0.0187	CbGpPWpGaD
Lenalidomide—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000513	0.0738	CbGdCrCtD
Lenalidomide—CDH5—Signaling by VEGF—TYK2—psoriasis	0.000493	0.0177	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000399	0.0574	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000399	0.0574	CbGdCrCtD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000393	0.0141	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.00039	0.0561	CbGdCrCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000376	0.0135	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—psoriasis	0.000369	0.0133	CbGpPWpGaD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000356	0.0128	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—psoriasis	0.000348	0.0125	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HCAR2—psoriasis	0.000317	0.0114	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.00031	0.0111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TAGAP—psoriasis	0.000275	0.00987	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000261	0.00936	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—psoriasis	0.000255	0.00917	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000251	0.00901	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000244	0.00877	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6—psoriasis	0.000241	0.00865	CbGpPWpGaD
Lenalidomide—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000241	0.0346	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000241	0.0346	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000235	0.0338	CbGdCrCtD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000228	0.00818	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000211	0.00758	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.00021	0.00755	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000204	0.00734	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000201	0.0072	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000198	0.00713	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.000187	0.00673	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	0.00017	0.00611	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL20—psoriasis	0.000165	0.00591	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000163	0.00585	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	0.000162	0.00582	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL13—psoriasis	0.000162	0.00582	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000158	0.00567	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000149	0.00535	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	0.000148	0.0053	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000143	0.00512	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000139	0.005	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	0.000139	0.00499	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000139	0.00498	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	0.000137	0.00493	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000135	0.00486	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000121	0.00435	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000113	0.00405	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000112	0.00402	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	0.00011	0.00396	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000108	0.00387	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000105	0.00376	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	0.000101	0.00364	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL10—psoriasis	0.000101	0.00364	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL4—psoriasis	0.000101	0.00362	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL4—psoriasis	9.86e-05	0.00354	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	9.78e-05	0.00351	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-B—psoriasis	9.64e-05	0.00346	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	9.63e-05	0.00346	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	9.2e-05	0.0033	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SOCS1—psoriasis	9.07e-05	0.00326	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	8.97e-05	0.00322	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-A—psoriasis	8.93e-05	0.00321	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—LEP—psoriasis	8.53e-05	0.00306	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	8.39e-05	0.00301	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	8.16e-05	0.00293	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	8.01e-05	0.00288	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—NOS2—psoriasis	7.95e-05	0.00285	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	7.84e-05	0.00282	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD4—psoriasis	7.73e-05	0.00278	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	7.71e-05	0.00277	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LEP—psoriasis	6.69e-05	0.0024	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOE—psoriasis	6.69e-05	0.0024	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	6.44e-05	0.00231	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	6.42e-05	0.0023	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NFKBIA—psoriasis	6.23e-05	0.00224	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IFNG—psoriasis	6.1e-05	0.00219	CbGpPWpGaD
Lenalidomide—Discomfort—Betamethasone—psoriasis	6.05e-05	0.000154	CcSEcCtD
Lenalidomide—Discomfort—Dexamethasone—psoriasis	6.05e-05	0.000154	CcSEcCtD
Lenalidomide—Dyspepsia—Hydrocortisone—psoriasis	6.05e-05	0.000154	CcSEcCtD
Lenalidomide—Haemoglobin—Methotrexate—psoriasis	6.05e-05	0.000154	CcSEcCtD
Lenalidomide—Rash—Mycophenolic acid—psoriasis	6.03e-05	0.000153	CcSEcCtD
Lenalidomide—Dermatitis—Mycophenolic acid—psoriasis	6.02e-05	0.000153	CcSEcCtD
Lenalidomide—Pain—Prednisolone—psoriasis	6.02e-05	0.000153	CcSEcCtD
Lenalidomide—Hepatitis—Methotrexate—psoriasis	6.02e-05	0.000153	CcSEcCtD
Lenalidomide—Haemorrhage—Methotrexate—psoriasis	6.02e-05	0.000153	CcSEcCtD
Lenalidomide—Urticaria—Mycophenolate mofetil—psoriasis	5.99e-05	0.000152	CcSEcCtD
Lenalidomide—Headache—Mycophenolic acid—psoriasis	5.99e-05	0.000152	CcSEcCtD
Lenalidomide—Decreased appetite—Hydrocortisone—psoriasis	5.98e-05	0.000152	CcSEcCtD
Lenalidomide—Pharyngitis—Methotrexate—psoriasis	5.97e-05	0.000152	CcSEcCtD
Lenalidomide—Abdominal pain—Mycophenolate mofetil—psoriasis	5.96e-05	0.000152	CcSEcCtD
Lenalidomide—Body temperature increased—Mycophenolate mofetil—psoriasis	5.96e-05	0.000152	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IFNG—psoriasis	5.96e-05	0.00214	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.95e-05	0.00214	CbGpPWpGaD
Lenalidomide—Urinary tract disorder—Methotrexate—psoriasis	5.94e-05	0.000151	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.93e-05	0.000151	CcSEcCtD
Lenalidomide—Fatigue—Hydrocortisone—psoriasis	5.93e-05	0.000151	CcSEcCtD
Lenalidomide—Vision blurred—Prednisone—psoriasis	5.91e-05	0.00015	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—psoriasis	5.9e-05	0.00015	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.9e-05	0.00015	CcSEcCtD
Lenalidomide—Pain—Hydrocortisone—psoriasis	5.88e-05	0.000149	CcSEcCtD
Lenalidomide—Oedema—Betamethasone—psoriasis	5.87e-05	0.000149	CcSEcCtD
Lenalidomide—Oedema—Dexamethasone—psoriasis	5.87e-05	0.000149	CcSEcCtD
Lenalidomide—Insomnia—Triamcinolone—psoriasis	5.85e-05	0.000149	CcSEcCtD
Lenalidomide—Infection—Betamethasone—psoriasis	5.83e-05	0.000148	CcSEcCtD
Lenalidomide—Infection—Dexamethasone—psoriasis	5.83e-05	0.000148	CcSEcCtD
Lenalidomide—Ill-defined disorder—Prednisone—psoriasis	5.81e-05	0.000148	CcSEcCtD
Lenalidomide—Paraesthesia—Triamcinolone—psoriasis	5.81e-05	0.000148	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisolone—psoriasis	5.8e-05	0.000147	CcSEcCtD
Lenalidomide—Visual impairment—Methotrexate—psoriasis	5.8e-05	0.000147	CcSEcCtD
Lenalidomide—Anaemia—Prednisone—psoriasis	5.79e-05	0.000147	CcSEcCtD
Lenalidomide—Shock—Betamethasone—psoriasis	5.78e-05	0.000147	CcSEcCtD
Lenalidomide—Shock—Dexamethasone—psoriasis	5.78e-05	0.000147	CcSEcCtD
Lenalidomide—Dyspnoea—Triamcinolone—psoriasis	5.77e-05	0.000147	CcSEcCtD
Lenalidomide—Nervous system disorder—Dexamethasone—psoriasis	5.76e-05	0.000146	CcSEcCtD
Lenalidomide—Nervous system disorder—Betamethasone—psoriasis	5.76e-05	0.000146	CcSEcCtD
Lenalidomide—Agitation—Prednisone—psoriasis	5.76e-05	0.000146	CcSEcCtD
Lenalidomide—Thrombocytopenia—Dexamethasone—psoriasis	5.75e-05	0.000146	CcSEcCtD
Lenalidomide—Thrombocytopenia—Betamethasone—psoriasis	5.75e-05	0.000146	CcSEcCtD
Lenalidomide—Tachycardia—Betamethasone—psoriasis	5.73e-05	0.000146	CcSEcCtD
Lenalidomide—Tachycardia—Dexamethasone—psoriasis	5.73e-05	0.000146	CcSEcCtD
Lenalidomide—Angioedema—Prednisone—psoriasis	5.73e-05	0.000146	CcSEcCtD
Lenalidomide—Hypersensitivity—Cyclosporine—psoriasis	5.7e-05	0.000145	CcSEcCtD
Lenalidomide—Dyspepsia—Triamcinolone—psoriasis	5.7e-05	0.000145	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—psoriasis	5.69e-05	0.000145	CcSEcCtD
Lenalidomide—Nausea—Mycophenolic acid—psoriasis	5.68e-05	0.000144	CcSEcCtD
Lenalidomide—Hyperhidrosis—Dexamethasone—psoriasis	5.68e-05	0.000144	CcSEcCtD
Lenalidomide—Hyperhidrosis—Betamethasone—psoriasis	5.68e-05	0.000144	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	5.67e-05	0.00204	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Hydrocortisone—psoriasis	5.66e-05	0.000144	CcSEcCtD
Lenalidomide—Malaise—Prednisone—psoriasis	5.65e-05	0.000144	CcSEcCtD
Lenalidomide—Vertigo—Prednisone—psoriasis	5.63e-05	0.000143	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—psoriasis	5.62e-05	0.000143	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Hydrocortisone—psoriasis	5.62e-05	0.000143	CcSEcCtD
Lenalidomide—Syncope—Prednisone—psoriasis	5.62e-05	0.000143	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—psoriasis	5.61e-05	0.000143	CcSEcCtD
Lenalidomide—Anorexia—Betamethasone—psoriasis	5.6e-05	0.000142	CcSEcCtD
Lenalidomide—Anorexia—Dexamethasone—psoriasis	5.6e-05	0.000142	CcSEcCtD
Lenalidomide—Urticaria—Prednisolone—psoriasis	5.59e-05	0.000142	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—psoriasis	5.58e-05	0.000142	CcSEcCtD
Lenalidomide—Fatigue—Triamcinolone—psoriasis	5.58e-05	0.000142	CcSEcCtD
Lenalidomide—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.56e-05	0.000141	CcSEcCtD
Lenalidomide—Asthenia—Cyclosporine—psoriasis	5.55e-05	0.000141	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—psoriasis	5.54e-05	0.00199	CbGpPWpGaD
Lenalidomide—Pain—Triamcinolone—psoriasis	5.53e-05	0.000141	CcSEcCtD
Lenalidomide—Loss of consciousness—Prednisone—psoriasis	5.51e-05	0.00014	CcSEcCtD
Lenalidomide—Hypotension—Betamethasone—psoriasis	5.49e-05	0.00014	CcSEcCtD
Lenalidomide—Hypotension—Dexamethasone—psoriasis	5.49e-05	0.00014	CcSEcCtD
Lenalidomide—Pruritus—Cyclosporine—psoriasis	5.47e-05	0.000139	CcSEcCtD
Lenalidomide—Urticaria—Hydrocortisone—psoriasis	5.46e-05	0.000139	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—psoriasis	5.46e-05	0.000139	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—NDUFA5—psoriasis	5.44e-05	0.00195	CbGpPWpGaD
Lenalidomide—Immune system disorder—Methotrexate—psoriasis	5.43e-05	0.000138	CcSEcCtD
Lenalidomide—Abdominal pain—Hydrocortisone—psoriasis	5.43e-05	0.000138	CcSEcCtD
Lenalidomide—Body temperature increased—Hydrocortisone—psoriasis	5.43e-05	0.000138	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—psoriasis	5.42e-05	0.000138	CcSEcCtD
Lenalidomide—Asthenia—Mycophenolate mofetil—psoriasis	5.41e-05	0.000138	CcSEcCtD
Lenalidomide—Hypertension—Prednisone—psoriasis	5.41e-05	0.000138	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	5.41e-05	0.00194	CbGpPWpGaD
Lenalidomide—Chills—Methotrexate—psoriasis	5.4e-05	0.000137	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.35e-05	0.000136	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Betamethasone—psoriasis	5.35e-05	0.000136	CcSEcCtD
Lenalidomide—Pruritus—Mycophenolate mofetil—psoriasis	5.34e-05	0.000136	CcSEcCtD
Lenalidomide—Myalgia—Prednisone—psoriasis	5.33e-05	0.000136	CcSEcCtD
Lenalidomide—Arthralgia—Prednisone—psoriasis	5.33e-05	0.000136	CcSEcCtD
Lenalidomide—Feeling abnormal—Triamcinolone—psoriasis	5.33e-05	0.000136	CcSEcCtD
Lenalidomide—Anxiety—Prednisone—psoriasis	5.32e-05	0.000135	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—psoriasis	5.32e-05	0.000135	CcSEcCtD
Lenalidomide—Insomnia—Dexamethasone—psoriasis	5.31e-05	0.000135	CcSEcCtD
Lenalidomide—Insomnia—Betamethasone—psoriasis	5.31e-05	0.000135	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.3e-05	0.000135	CcSEcCtD
Lenalidomide—Diarrhoea—Cyclosporine—psoriasis	5.29e-05	0.000135	CcSEcCtD
Lenalidomide—Paraesthesia—Dexamethasone—psoriasis	5.27e-05	0.000134	CcSEcCtD
Lenalidomide—Paraesthesia—Betamethasone—psoriasis	5.27e-05	0.000134	CcSEcCtD
Lenalidomide—Discomfort—Prednisone—psoriasis	5.27e-05	0.000134	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—psoriasis	5.27e-05	0.000134	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—psoriasis	5.24e-05	0.000133	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—psoriasis	5.24e-05	0.000133	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.2e-05	0.00187	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Prednisolone—psoriasis	5.19e-05	0.000132	CcSEcCtD
Lenalidomide—Dyspepsia—Betamethasone—psoriasis	5.17e-05	0.000131	CcSEcCtD
Lenalidomide—Dyspepsia—Dexamethasone—psoriasis	5.17e-05	0.000131	CcSEcCtD
Lenalidomide—Diarrhoea—Mycophenolate mofetil—psoriasis	5.16e-05	0.000131	CcSEcCtD
Lenalidomide—Urticaria—Triamcinolone—psoriasis	5.14e-05	0.000131	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—psoriasis	5.13e-05	0.00013	CcSEcCtD
Lenalidomide—Body temperature increased—Triamcinolone—psoriasis	5.12e-05	0.00013	CcSEcCtD
Lenalidomide—Dizziness—Cyclosporine—psoriasis	5.11e-05	0.00013	CcSEcCtD
Lenalidomide—Oedema—Prednisone—psoriasis	5.11e-05	0.00013	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TYK2—psoriasis	5.11e-05	0.00183	CbGpPWpGaD
Lenalidomide—Decreased appetite—Dexamethasone—psoriasis	5.1e-05	0.00013	CcSEcCtD
Lenalidomide—Decreased appetite—Betamethasone—psoriasis	5.1e-05	0.00013	CcSEcCtD
Lenalidomide—Infection—Prednisone—psoriasis	5.08e-05	0.000129	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.07e-05	0.00182	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Betamethasone—psoriasis	5.07e-05	0.000129	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Dexamethasone—psoriasis	5.07e-05	0.000129	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—psoriasis	5.07e-05	0.000129	CcSEcCtD
Lenalidomide—Hypersensitivity—Hydrocortisone—psoriasis	5.06e-05	0.000129	CcSEcCtD
Lenalidomide—Fatigue—Dexamethasone—psoriasis	5.06e-05	0.000129	CcSEcCtD
Lenalidomide—Fatigue—Betamethasone—psoriasis	5.06e-05	0.000129	CcSEcCtD
Lenalidomide—Shock—Prednisone—psoriasis	5.03e-05	0.000128	CcSEcCtD
Lenalidomide—Pain—Betamethasone—psoriasis	5.02e-05	0.000128	CcSEcCtD
Lenalidomide—Pain—Dexamethasone—psoriasis	5.02e-05	0.000128	CcSEcCtD
Lenalidomide—Nervous system disorder—Prednisone—psoriasis	5.02e-05	0.000128	CcSEcCtD
Lenalidomide—Tachycardia—Prednisone—psoriasis	4.99e-05	0.000127	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	4.99e-05	0.00179	CbGpPWpGaD
Lenalidomide—Dizziness—Mycophenolate mofetil—psoriasis	4.99e-05	0.000127	CcSEcCtD
Lenalidomide—Skin disorder—Prednisone—psoriasis	4.97e-05	0.000126	CcSEcCtD
Lenalidomide—Hyperhidrosis—Prednisone—psoriasis	4.94e-05	0.000126	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—psoriasis	4.94e-05	0.000126	CcSEcCtD
Lenalidomide—Asthenia—Hydrocortisone—psoriasis	4.93e-05	0.000125	CcSEcCtD
Lenalidomide—Vomiting—Cyclosporine—psoriasis	4.92e-05	0.000125	CcSEcCtD
Lenalidomide—Rash—Cyclosporine—psoriasis	4.88e-05	0.000124	CcSEcCtD
Lenalidomide—Anorexia—Prednisone—psoriasis	4.87e-05	0.000124	CcSEcCtD
Lenalidomide—Dermatitis—Cyclosporine—psoriasis	4.87e-05	0.000124	CcSEcCtD
Lenalidomide—Pruritus—Hydrocortisone—psoriasis	4.86e-05	0.000124	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—psoriasis	4.86e-05	0.000124	CcSEcCtD
Lenalidomide—Headache—Cyclosporine—psoriasis	4.85e-05	0.000123	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—psoriasis	4.84e-05	0.000123	CcSEcCtD
Lenalidomide—Feeling abnormal—Betamethasone—psoriasis	4.84e-05	0.000123	CcSEcCtD
Lenalidomide—Feeling abnormal—Dexamethasone—psoriasis	4.84e-05	0.000123	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Dexamethasone—psoriasis	4.8e-05	0.000122	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Betamethasone—psoriasis	4.8e-05	0.000122	CcSEcCtD
Lenalidomide—Vomiting—Mycophenolate mofetil—psoriasis	4.8e-05	0.000122	CcSEcCtD
Lenalidomide—Hypersensitivity—Triamcinolone—psoriasis	4.77e-05	0.000121	CcSEcCtD
Lenalidomide—Rash—Mycophenolate mofetil—psoriasis	4.76e-05	0.000121	CcSEcCtD
Lenalidomide—Dermatitis—Mycophenolate mofetil—psoriasis	4.75e-05	0.000121	CcSEcCtD
Lenalidomide—Headache—Mycophenolate mofetil—psoriasis	4.73e-05	0.00012	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—psoriasis	4.72e-05	0.00012	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—psoriasis	4.71e-05	0.00012	CcSEcCtD
Lenalidomide—Diarrhoea—Hydrocortisone—psoriasis	4.7e-05	0.00012	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—psoriasis	4.69e-05	0.000119	CcSEcCtD
Lenalidomide—Urticaria—Dexamethasone—psoriasis	4.67e-05	0.000119	CcSEcCtD
Lenalidomide—Urticaria—Betamethasone—psoriasis	4.67e-05	0.000119	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Prednisone—psoriasis	4.66e-05	0.000118	CcSEcCtD
Lenalidomide—Dizziness—Prednisolone—psoriasis	4.65e-05	0.000118	CcSEcCtD
Lenalidomide—Asthenia—Triamcinolone—psoriasis	4.64e-05	0.000118	CcSEcCtD
Lenalidomide—Body temperature increased—Dexamethasone—psoriasis	4.64e-05	0.000118	CcSEcCtD
Lenalidomide—Abdominal pain—Betamethasone—psoriasis	4.64e-05	0.000118	CcSEcCtD
Lenalidomide—Abdominal pain—Dexamethasone—psoriasis	4.64e-05	0.000118	CcSEcCtD
Lenalidomide—Body temperature increased—Betamethasone—psoriasis	4.64e-05	0.000118	CcSEcCtD
Lenalidomide—Insomnia—Prednisone—psoriasis	4.63e-05	0.000118	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—CYP2S1—psoriasis	4.62e-05	0.00166	CbGpPWpGaD
Lenalidomide—Nausea—Cyclosporine—psoriasis	4.59e-05	0.000117	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisone—psoriasis	4.59e-05	0.000117	CcSEcCtD
Lenalidomide—Pruritus—Triamcinolone—psoriasis	4.58e-05	0.000116	CcSEcCtD
Lenalidomide—Cough—Methotrexate—psoriasis	4.57e-05	0.000116	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.56e-05	0.00164	CbGpPWpGaD
Lenalidomide—Dizziness—Hydrocortisone—psoriasis	4.55e-05	0.000116	CcSEcCtD
Lenalidomide—Dyspepsia—Prednisone—psoriasis	4.5e-05	0.000114	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.5e-05	0.00162	CbGpPWpGaD
Lenalidomide—Nausea—Mycophenolate mofetil—psoriasis	4.48e-05	0.000114	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—psoriasis	4.46e-05	0.000113	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—psoriasis	4.46e-05	0.000113	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—psoriasis	4.46e-05	0.000113	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—psoriasis	4.45e-05	0.0016	CbGpPWpGaD
Lenalidomide—Decreased appetite—Prednisone—psoriasis	4.45e-05	0.000113	CcSEcCtD
Lenalidomide—Rash—Prednisolone—psoriasis	4.44e-05	0.000113	CcSEcCtD
Lenalidomide—Dermatitis—Prednisolone—psoriasis	4.43e-05	0.000113	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.43e-05	0.000113	CcSEcCtD
Lenalidomide—Fatigue—Prednisone—psoriasis	4.41e-05	0.000112	CcSEcCtD
Lenalidomide—Headache—Prednisolone—psoriasis	4.41e-05	0.000112	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—psoriasis	4.41e-05	0.000112	CcSEcCtD
Lenalidomide—Constipation—Prednisone—psoriasis	4.37e-05	0.000111	CcSEcCtD
Lenalidomide—Vomiting—Hydrocortisone—psoriasis	4.37e-05	0.000111	CcSEcCtD
Lenalidomide—Rash—Hydrocortisone—psoriasis	4.33e-05	0.00011	CcSEcCtD
Lenalidomide—Dermatitis—Hydrocortisone—psoriasis	4.33e-05	0.00011	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—psoriasis	4.31e-05	0.00011	CcSEcCtD
Lenalidomide—Headache—Hydrocortisone—psoriasis	4.31e-05	0.00011	CcSEcCtD
Lenalidomide—Dizziness—Triamcinolone—psoriasis	4.28e-05	0.000109	CcSEcCtD
Lenalidomide—Infection—Methotrexate—psoriasis	4.25e-05	0.000108	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisone—psoriasis	4.21e-05	0.000107	CcSEcCtD
Lenalidomide—Asthenia—Betamethasone—psoriasis	4.21e-05	0.000107	CcSEcCtD
Lenalidomide—Asthenia—Dexamethasone—psoriasis	4.21e-05	0.000107	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—psoriasis	4.19e-05	0.000107	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—psoriasis	4.18e-05	0.000106	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Prednisone—psoriasis	4.18e-05	0.000106	CcSEcCtD
Lenalidomide—Nausea—Prednisolone—psoriasis	4.18e-05	0.000106	CcSEcCtD
Lenalidomide—Pruritus—Dexamethasone—psoriasis	4.15e-05	0.000106	CcSEcCtD
Lenalidomide—Pruritus—Betamethasone—psoriasis	4.15e-05	0.000106	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—psoriasis	4.15e-05	0.000106	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—JUN—psoriasis	4.13e-05	0.00148	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Methotrexate—psoriasis	4.13e-05	0.000105	CcSEcCtD
Lenalidomide—Vomiting—Triamcinolone—psoriasis	4.11e-05	0.000105	CcSEcCtD
Lenalidomide—Nausea—Hydrocortisone—psoriasis	4.08e-05	0.000104	CcSEcCtD
Lenalidomide—Rash—Triamcinolone—psoriasis	4.08e-05	0.000104	CcSEcCtD
Lenalidomide—Dermatitis—Triamcinolone—psoriasis	4.08e-05	0.000104	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—psoriasis	4.07e-05	0.000104	CcSEcCtD
Lenalidomide—Urticaria—Prednisone—psoriasis	4.06e-05	0.000103	CcSEcCtD
Lenalidomide—Headache—Triamcinolone—psoriasis	4.05e-05	0.000103	CcSEcCtD
Lenalidomide—Abdominal pain—Prednisone—psoriasis	4.04e-05	0.000103	CcSEcCtD
Lenalidomide—Body temperature increased—Prednisone—psoriasis	4.04e-05	0.000103	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	4.03e-05	0.00145	CbGpPWpGaD
Lenalidomide—Diarrhoea—Betamethasone—psoriasis	4.02e-05	0.000102	CcSEcCtD
Lenalidomide—Diarrhoea—Dexamethasone—psoriasis	4.02e-05	0.000102	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—psoriasis	3.99e-05	0.000102	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NFKB1—psoriasis	3.98e-05	0.00143	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—psoriasis	3.95e-05	0.00142	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—psoriasis	3.89e-05	9.9e-05	CcSEcCtD
Lenalidomide—Dizziness—Dexamethasone—psoriasis	3.88e-05	9.88e-05	CcSEcCtD
Lenalidomide—Dizziness—Betamethasone—psoriasis	3.88e-05	9.88e-05	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—psoriasis	3.87e-05	9.83e-05	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TNF—psoriasis	3.86e-05	0.00138	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NDUFA5—psoriasis	3.86e-05	0.00138	CbGpPWpGaD
Lenalidomide—Nausea—Triamcinolone—psoriasis	3.84e-05	9.78e-05	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—psoriasis	3.84e-05	9.76e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.83e-05	0.00138	CbGpPWpGaD
Lenalidomide—Dyspnoea—Methotrexate—psoriasis	3.81e-05	9.69e-05	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—psoriasis	3.8e-05	9.66e-05	CcSEcCtD
Lenalidomide—Hypersensitivity—Prednisone—psoriasis	3.77e-05	9.58e-05	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—psoriasis	3.76e-05	9.57e-05	CcSEcCtD
Lenalidomide—Vomiting—Betamethasone—psoriasis	3.73e-05	9.5e-05	CcSEcCtD
Lenalidomide—Vomiting—Dexamethasone—psoriasis	3.73e-05	9.5e-05	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—psoriasis	3.72e-05	9.45e-05	CcSEcCtD
Lenalidomide—Rash—Dexamethasone—psoriasis	3.7e-05	9.42e-05	CcSEcCtD
Lenalidomide—Rash—Betamethasone—psoriasis	3.7e-05	9.42e-05	CcSEcCtD
Lenalidomide—Dermatitis—Dexamethasone—psoriasis	3.7e-05	9.41e-05	CcSEcCtD
Lenalidomide—Dermatitis—Betamethasone—psoriasis	3.7e-05	9.41e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—psoriasis	3.69e-05	9.38e-05	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—psoriasis	3.68e-05	9.37e-05	CcSEcCtD
Lenalidomide—Headache—Dexamethasone—psoriasis	3.68e-05	9.36e-05	CcSEcCtD
Lenalidomide—Headache—Betamethasone—psoriasis	3.68e-05	9.36e-05	CcSEcCtD
Lenalidomide—Asthenia—Prednisone—psoriasis	3.67e-05	9.33e-05	CcSEcCtD
Lenalidomide—Pain—Methotrexate—psoriasis	3.65e-05	9.29e-05	CcSEcCtD
Lenalidomide—Pruritus—Prednisone—psoriasis	3.62e-05	9.2e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—psoriasis	3.61e-05	0.0013	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.59e-05	0.00129	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.58e-05	0.00129	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—psoriasis	3.58e-05	0.00128	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Methotrexate—psoriasis	3.52e-05	8.96e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Prednisone—psoriasis	3.5e-05	8.9e-05	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—psoriasis	3.49e-05	8.89e-05	CcSEcCtD
Lenalidomide—Nausea—Betamethasone—psoriasis	3.49e-05	8.87e-05	CcSEcCtD
Lenalidomide—Nausea—Dexamethasone—psoriasis	3.49e-05	8.87e-05	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—psoriasis	3.48e-05	0.00125	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.45e-05	0.00124	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.42e-05	0.00123	CbGpPWpGaD
Lenalidomide—Urticaria—Methotrexate—psoriasis	3.4e-05	8.63e-05	CcSEcCtD
Lenalidomide—Dizziness—Prednisone—psoriasis	3.38e-05	8.6e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—psoriasis	3.38e-05	8.59e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—psoriasis	3.38e-05	8.59e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—CYP2S1—psoriasis	3.28e-05	0.00118	CbGpPWpGaD
Lenalidomide—Vomiting—Prednisone—psoriasis	3.25e-05	8.27e-05	CcSEcCtD
Lenalidomide—Rash—Prednisone—psoriasis	3.22e-05	8.2e-05	CcSEcCtD
Lenalidomide—Dermatitis—Prednisone—psoriasis	3.22e-05	8.19e-05	CcSEcCtD
Lenalidomide—Headache—Prednisone—psoriasis	3.2e-05	8.15e-05	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—psoriasis	3.18e-05	0.00114	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Methotrexate—psoriasis	3.15e-05	8.01e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.13e-05	0.00112	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—psoriasis	3.07e-05	7.8e-05	CcSEcCtD
Lenalidomide—Nausea—Prednisone—psoriasis	3.04e-05	7.72e-05	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—psoriasis	3.02e-05	7.69e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—psoriasis	2.92e-05	7.44e-05	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—psoriasis	2.83e-05	7.19e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TP53—psoriasis	2.73e-05	0.00098	CbGpPWpGaD
Lenalidomide—Vomiting—Methotrexate—psoriasis	2.72e-05	6.91e-05	CcSEcCtD
Lenalidomide—Rash—Methotrexate—psoriasis	2.69e-05	6.85e-05	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—psoriasis	2.69e-05	6.85e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.68e-05	0.000964	CbGpPWpGaD
Lenalidomide—Headache—Methotrexate—psoriasis	2.68e-05	6.81e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.54e-05	0.000913	CbGpPWpGaD
Lenalidomide—Nausea—Methotrexate—psoriasis	2.54e-05	6.46e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL6—psoriasis	2.5e-05	0.000897	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.45e-05	0.000879	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.42e-05	0.00087	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.37e-05	0.00085	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CARM1—psoriasis	2.26e-05	0.000811	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.22e-05	0.000797	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.11e-05	0.000758	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.9e-05	0.000683	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.68e-05	0.000602	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CARM1—psoriasis	1.6e-05	0.000575	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAT—psoriasis	1.39e-05	0.000499	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HLA-A—psoriasis	1.38e-05	0.000496	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOE—psoriasis	1.29e-05	0.000463	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS2—psoriasis	1.2e-05	0.000431	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOE—psoriasis	1.08e-05	0.000388	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAT—psoriasis	9.85e-06	0.000354	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TYK2—psoriasis	9.84e-06	0.000353	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—psoriasis	9.4e-06	0.000338	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—psoriasis	8.9e-06	0.000319	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOE—psoriasis	7.65e-06	0.000275	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—psoriasis	6.89e-06	0.000247	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—psoriasis	6.66e-06	0.000239	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—psoriasis	4.81e-06	0.000173	CbGpPWpGaD
